Meeting
2020 ASCO Virtual Scientific Program
Combination anti-PD-1 and ipilimumab (ipi) therapy in patients with advanced melanoma and pre-existing autoimmune disorders (AD).
Authors
Lauren Julia Brown
Crown Princess Mary Cancer Care Centre, Westmead, NSW, Australia
Lauren Julia Brown , Alison Weppler , Prachi Bhave , Clara Allayous , James Randall Patrinely , Patrick Alexander Ott , Shahneen Kaur Sandhu , Andrew Mark Haydon , Celeste Lebbe , Douglas Buckner Johnson , Georgina V. Long , Alexander M. Menzies , Matteo S. Carlino
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 38: 2020 (suppl; abstr 10026)
DOI
10.1200/JCO.2020.38.15_suppl.10026
Abstract #
10026
Poster Bd #
375
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Standard-dose pembrolizumab (pembro) plus alternate-dose ipilimumab (ipi) in advanced melanoma: Initial analysis of KEYNOTE-029 cohort 1C.
First Author: Georgina V. Long
Poster
2016 ASCO Annual Meeting
Derivation and validation of a prediction scale for response to PD-1 monotherapy.
First Author: Adi Nosrati
Poster
2015 ASCO Annual Meeting
Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): Data from the KEYNOTE-029 phase 1 study.
First Author: Michael B. Atkins
Poster
2023 ASCO Annual Meeting
Efficacy of adjuvant therapy in patients (pts) with AJCC v8 stage IIIA cutaneous melanoma.
First Author: Piyush Grover